At 02:47 PM on Monday, the Nifty Pharma index was top loser among sectoral indices down 1.8% as against 0.3% rise in the Nifty 50.
Strong custom synthesis growth, improving margins and projects nearing commercialisation support Divi's Labs' outlook, though elevated valuations remain a concern for analysts
Divi's Labs, Laurus Labs, Sai Life Sciences and Glenmark Pharma quoted at their respective record highs in Monday's trade.
The stock price of Divi's Labs quoted higher for the 12th straight trading day, surging 32 per cent during the period.
Divi's Laboratories Ltd on Saturday posted a sharp 63.57 per cent rise in net profit to Rs 1,127 crore in the September quarter due to higher revenues. The company posted a net profit of Rs 689 crore in the corresponding period of the previous fiscal year, a regulatory filing said. Revenue from operations rose 35.39 per cent to Rs 3,676 crore during the second quarter of FY27 from Rs 2,715 crore a year earlier, it said. Its total expenses rose to Rs 2,265 crore in the period under review from Rs 1,948 crore a year ago, it added. The company's net profit for the first half of the current fiscal year, however, declined 35.39 per cent to Rs 2,029 crore from Rs 2,568 crore in the year-ago period, the filing added.
Pharma stocks on a roll: Symbiotec Pharmalab, Windlas Biotech, Sai Life Sciences, Alembic Pharmaceuticals and Fermation Biotech were up in the range of 9-20% on Friday.
Indian Hotels Company, PVR Inox and Zydus Lifesciences from the BSE 500 index have hit their respective 52-week highs.
Stocks to buy today: Chandan Taparia of MOFSL has shared a bullish outlook on Bharti Airtel, Paytm, and Divi's Lab.
Divi's Laboratories remains the top pick for most brokerages in this segment, even as valuations turn rich after the sharp rally
Nifty has to hold above the 22,700 zones for an upside move towards 22,900, then 23,000 zones, while support can be seen at 22,600.
Brokerages expect diagnostic majors to sustain volume growth through FY27, aided by robust demand and stable pricing, though the recent stock rally may cap upside
Till Nifty holds below 23,700, weakness could extend towards 23,500, then 23,400 levels, while on the upside, hurdles can be seen at 23,800, then 23,900 zones.
India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.
Chandan Taparia of MOFSL recommends buying Divi's Laboratories, TVS Motors and Dixon Technologies, citing strong technical setups and improving momentum.
Chandan Taparia of Motilal Oswal Financial Services has recommended three stocks to buy today: Divi's Laboratories, MCX, and Eternal.
In the past month, Divi's Labs outperformed the market by soaring 25 per cent, as against a 1.2 per cent rise in the BSE Sensex.
Q1FY27 company results: Firms including Aarti Surfactants, Aditya Birla Lifestyle Brands, APL Apollo Tubes, and Utkarsh Small Finance Bank are also to release their April-June earnings today
The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.
Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.
Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.